Significant progress made in advancing strategic value chain
initiative including signing of strategic supply agreements, receipt
of long lead-time government permits and progress in advancing capex
investments

Switched to the new multi-source supply structure at the end of 2018
making a major step forward in thestrategic value chain
transition

On track to realize adjusted diluted EPS improvement of 10%, or $0.25
to $0.27 per share run rate by the end of 2019 from the value chain
and manufacturing optimization program

Received $20 millionNutrien payment and completed $23 million sale
leaseback in Q4

Financial Highlights

Full-year 2018 performance was in line with expectations with sales up
11% to $802 million, net income up 61% to $36 million, and Adjusted
EBITDA up 4% to $125 million, compared with 2017

Q4 Sales of $193 million were flat compared with the prior-year
quarter as stabilized base business and pricing power were partially
offset by the planned discontinuation of a portion of low-margin
nutrition trading business

Q4 GAAP Net Income of $5 million, or $0.24 per share, was 143% ahead
of Q4 2017 due primarily to tax reform charges in the prior year
quarter

Q4 Adjusted EBITDA of $30 million was up 10% and adjusted EBITDA
margin was up 143 basis points year-over-year

Q4 Adjusted Diluted EPS increased 3% year-over-year to $0.54

Paid down $45 million in debt in Q4 resulting in net leverage of 2.2x

Average working capital for the quarter and the full year was 23% of
annualized sales

Management Comments

“2018 was an important year for Innophos as we executed against our
Vision 2022 strategic roadmap to transform the growth profile of the
Company, prepare for a sustainably lower cost structure and develop
science-backed solutions that better serve our customers and enhance our
position in attractive Food, Health and Nutrition end-markets,” said Kim
Ann Mink, Ph.D., Chairman, President and Chief Executive Officer.
“Notably, before the end of the year, we achieved a major milestone with
our strategic value chain program as our Geismar facility was switched
to the new supply chain structure and is now taking intermediate product
from internal as well as external sources per the new supply agreements
that were completed in 2018.

“Our Q4 financial performance was in line with our expectations on both
the top and bottom line as we capitalized on the stability of our base
business, leveraged our pricing power and reduced operating expense. On
a full-year basis, we grew sales by 11%, GAAP Net Income by 61% and
adjusted EBITDA by 4%. In addition, by remaining disciplined with the
management of our liquidity position, we further reduced our debt
position and ended the year with net leverage of 2.2x.

“We have continued to take actions to proactively manage near-term
market dynamics while simultaneously advancing our key initiatives under
our Strategic Pillars,” said Mink. “Our priorities this year are to
continue executing against the Strategic Pillar key initiatives. These
include completing the transition of the multi-faceted strategic value
chain repositioning, continuing to leverage our value selling to capture
price increases, and delivering wins through our SPARC new product
development program to drive organic growth. Further, we remain
disciplined in our evaluation of M&A opportunities that meet our
financial and strategic criteria."

Q4 2018 Results

Variance $ and Variance % in the following tables and comments may
not foot due to rounding

$ Millions except EPS

Quarter 4

2018

2017

Variance $

Variance %

Sales

193

193

0

0%

Net Income

5

(11)

16

143%

Adj. Net Income

11

10

0

4%

EBITDA

23

21

2

11%

Adj. EBITDA

30

27

3

10%

Diluted EPS

0.24

(0.58)

0.82

142%

Adj. Diluted EPS

0.54

0.52

0.02

3%

Cash from Ops

43

27

15

56%

Free Cash Flow

52

17

35

204%

Sales were in line with the prior year as the 3% increase in the base
business was offset by a decrease due to the previously communicated
decision to discontinue a portion of low-margin nutrition trading
business

GAAP Net Income of $5 million, and diluted EPS of $0.24, were up
versus the prior year due to tax reform provisions taken in the
prior-year period

The supply imbalance in Mexico’s natural gas network that was
communicated in the Company's Q3 release has continued and resulted in
sizable rate increases. Supply to the Southern part of the country,
where Innophos’ Coatzacoalcos facility is located, has been impacted
as a result of low levels of storage and pipeline investments falling
behind schedule. The impact in the quarter was $2 million, after $1
million of adjustments for non-GAAP purposes.

Adjusted EBITDA of $30 million was up 10% and Adjusted EBITDA margin
of 15% was up 143 basis points compared with Q4 2017, which included a
plant maintenance outage

Adjusted diluted EPS of $0.54 was up $0.02 year over year as the
increase in EBITDA was largely offset by a $0.07 impact from higher
tax rates

Free Cash Flow was $52 million, mostly driven by the receipt of the
$20 millionNutrien payment and $23 million from the sale leaseback
transaction completed in Q4 2018

Q4 2018 Segment Financials

Q4 Sales

2018 $ Millions

2017 $ Millions

Variance $

Variance %

FHN

113

116

(3)

-2%

IS

65

64

1

1%

Other

15

13

2

11%

Total IPHS

193

193

0

0%

Q4 Adj. EBITDA

2018 $ Millions

2017 $ Millions

2018 $ Margin

2017 $ Margin

FHN

17

22

15%

19%

IS

10

3

15%

4%

Other

3

3

22%

22%

Total IPHS

30

27

15%

14%

Note: See Adjusted EBITDA reconciliation to EBITDA in the
financial tables that follow

FHN sales declined 2% year over year (price +5%, volume -8%) as the
strength in the base portfolio was offset by the Company’s decision to
discontinue a portion of low-margin nutrition trading business;
adjusted EBITDA margins were sequentially similar to the past two
quarters but 377 bps below 2017 due to continued increases in freight
market rates and other input costs

IS sales were up 1% year over year (price +6%, volume -5%); adjusted
EBITDA margins were up markedly versus the prior-year quarter due to
the improved selling prices in 2018 and maintenance outage expense in
Q4 2017

Other sales were up 11% (price +22%, volume -11%) due primarily to
higher co-product prices; adjusted EBITDA margins were 22%, up 90 bps
from prior year

Year-to-Date Results

Variance $ and Variance % in the following tables and comments may
not foot due to rounding

GAAP Net Income of $36 million was up $14 million due primarily to tax
reform charges in the prior year

Adjusted EBITDA grew 4% due to contributions from acquisitions as well
as base business price increases which offset input cost increases

Average working capital was 23% of annualized sales

YTD Quarter 4 Segment Financials

YTD Q4 Segment Sales

2018 $ Millions

2017 $ Millions

Variance $

Variance %

FHN

480

397

83

21%

IS

261

263

(2)

(1)%

Other

61

62

(1)

(2)%

Total IPHS

802

722

80

11%

YTD Q4 Segment Adj. EBITDA

2018 $ Millions

2017 $ Millions

2018 $ Margin

2017 $ Margin

FHN

73

75

15%

19%

IS

44

37

17%

14%

Other

8

8

13%

13%

Total IPHS

125

120

16%

17%

Note: See Adjusted EBITDA reconciliation to EBITDA in the
financial tables that follow

FHN represented 60% of total Company sales and was up 21% year over
year (price +3%, volume +18%) due to the contribution from
acquisitions and strength of the base portfolio; adjusted EBITDA
margins were 362 bps below 2017 due to the dilutive effects from
lower-margin acquisitions, isolated operational issues in Q3 and
higher freight costs

Margin contribution from business gains and new product
development, and

The strategic value chain program, which is on track to realize
adjusted diluted EPS improvement of 10%, or $0.25 to $0.27 per
share run rate by the end of 2019.

These gains are expected to be partly offset by:

Input cost increases for raw materials and freight, and

Higher costs related to the Mexico energy supply shortages that
are expected through H1 2019. The anticipated non-recurring
portion is expected to be adjusted for non-GAAP purposes.

From a GAAP and cash perspective, the expectation is that costs will be
higher during H1. The anticipated non-recurring portion is expected to
be adjusted for non-GAAP reporting purposes such as value chain
transition expense and Mexico natural gas supply adjustment charges.

Capital investments are expected to be in line with 2018 to
finalize the value chain and manufacturing optimization program that
commenced in 2018. Average working capital is estimated to remain
in line with 2018.

The Company expects its effective tax rate to operate in the
28-32% range.

Conference Call

Innophos will host its fourth-quarter 2018 conference call today
February 20, 2019 at 9:00 am ET to discuss its earnings results. Those
who wish to listen to the conference call webcast should visit the
“Investors” section of the Company’s website at www.innophos.com.
The live call also can be accessed by dialing (877) 604-1612 (U.S.) or
(201) 389-0883 (international). No passcode is required. Please dial in
approximately 15 minutes ahead of the start time to ensure timely entry
to the call. The Q4 2018 earnings call presentation will be made
available on the Company’s website
the morning of the call. If you are unable to listen to the live call,
the webcast will be archived on the Company’s website. In addition, a
replay of the call will be available between February 20 and March 6,
2019. The replay is accessible by dialing (877) 660-6853 (U.S.) or (201)
612-7415 (international) and entering the Conference ID number 13686718.

Additional information on Innophos’ fourth quarter 2018 results can also
be found on the Company’s website.

About the Company

Innophos is a leading international producer of specialty ingredient
solutions that deliver far-reaching, versatile benefits for the food,
health, nutrition and industrial markets. We leverage our expertise in
the science and technology of blending and formulating phosphate,
mineral, enzyme and botanical based ingredients to help our customers
offer products that are tasty, healthy, nutritious and economical.
Headquartered in Cranbury, New Jersey, Innophos has manufacturing
operations across the United States, in Canada, Mexico and China. For
more information, please visit www.innophos.com.
'IPHS-G'

Financial Tables Follow

Safe Harbor for Forward-Looking and Cautionary
Statements

This press release contains or may contain forward-looking statements
within the meaning of Section 27a of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. The Company intends these forward-looking statements to be
covered by the safe harbor provisions for such statements. Statements
made in this press release that relate to our future performance or
future financial results or other future events (which may be identified
by such terms as “expect”, “estimate”, “anticipate”, “assume”,
“believe”, “plan”, “intend’, “may”, “will”, “should”, “outlook”,
“guidance”, “target”, “opportunity”, “potential” or similar terms and
variations or the negative thereof) are forward-looking statements,
including the Company’s expectations regarding the business environment
and the Company’s overall guidance regarding future performance and
growth. These statements are based on our current beliefs and
expectations and are subject to significant risks and uncertainties.
Actual results may materially differ from the expectations expressed in
or implied by these forward-looking statements. Factors that could cause
the Company’s actual results to differ materially include, but are not
limited to: (1) global macroeconomic conditions and trends; (2) the
behavior of financial markets, including fluctuations in foreign
currencies, interest rates and turmoil in capital markets; (3) changes
in regulatory controls regarding tariffs, duties, taxes and income tax
rates; (4) the Company’s ability to implement and refine its Vision 2022
strategic roadmap; (5) the Company’s ability to successfully identify
and complete acquisitions in line with its Vision 2022 strategic roadmap
and effectively operate and integrate acquired businesses to realize the
anticipated benefits of those acquisitions; (6) the Company’s ability to
realize expected cost savings and efficiencies from its performance
improvement and other optimization initiatives; (7) the Company’s
ability to effectively compete in its markets, and to successfully
develop new and competitive products that appeal to its customers; (8)
changes in consumer preferences and demand for the Company’s products or
a decline in consumer confidence and spending; (9) the Company’s ability
to benefit from its investments in assets and human capital and the
ability to complete projects successfully and on budget; (10) economic,
regulatory and political risks associated with the Company’s
international operations, most notably Mexico and China; (11) volatility
and increases in the price of raw materials, energy and transportation,
and fluctuations in the quality and availability of raw materials and
process aids; (12) the impact of a disruption in the Company’s supply
chain or its relationship with its suppliers; (13) the Company’s ability
to comply with, and the costs associated with compliance with, U.S. and
foreign environmental protection laws and (14) the Company’s ability to
meet quality and regulatory standards in the various jurisdictions in
which it has operations or conducts business. We caution you to consider
the important risks and other factors as set forth in the
forward-looking statements section and in Item 1A Risk Factors in our
most recent Annual Report on Form 10-K, as amended by subsequent reports
on Forms 10-Q and 8-K. We do not undertake to update the forward-looking
statements to reflect the impact of circumstances or events that may
arise after the date of the forward-looking statements.

Summary Profit & Loss Statement

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Statement of Operations (Unaudited)

(Dollars in thousands, except per share amounts or share amounts)

Three Months EndedDecember 31,

Twelve Months EndedDecember 31,

2018

2017

2018

2017

Net Sales

$192,744

$193,100

$801,842

$722,024

Cost of goods sold

163,192

160,659

658,451

572,995

Gross profit

29,552

32,441

143,391

149,029

Operating expenses:

Selling, general and administrative

16,553

22,190

81,101

82,301

Research & development expenses

1,087

1,020

5,076

3,733

Total operating expenses

17,640

23,210

86,177

86,034

Operating income

11,912

9,231

57,214

62,995

Interest expense, net

3,993

2,572

13,523

7,008

Foreign exchange loss (gain)

119

(543

)

528

(578

)

Other income

(26

)

(30

)

(69

)

(72

)

Income before income taxes

7,826

7,232

43,232

56,637

(Benefit) provision for income taxes

3,006

18,515

7,161

34,192

Net income

$4,820

$(11,283

)

$36,071

$22,445

Diluted Earnings Per Participating Share

$0.24

$(0.58

)

$1.82

$1.13

Diluted weighted average participating shares outstanding

19,671,101

19,530,339

19,760,259

19,733,410

Dividends paid per share of common stock

$0.48

$0.48

$1.92

$1.92

Dividends declared per share of common stock

$0.48

$0.48

$1.92

$1.92

Adjusted Net Income Reconciliation to Net Income

(Dollars in thousands, except EPS)

Three Months EndedDecember 31,

Twelve Months EndedDecember 31,

2018

2017

2018

2017

Net Income

$4,820

$(11,283

)

$36,071

$22,445

Pre-tax Adjustments

Foreign exchange loss (gain)

119

(543

)

528

(578

)

Severance/Restructuring expense

(51

)

358

2,530

2,982

Inventory fair value adjustment

0

2,905

0

4,300

M&A related costs

1,212

2,325

2,194

5,279

Mexico natural gas supply imbalance charges

970

0

2,827

0

Value chain transition

3,002

0

9,880

0

Other

40

0

40

0

D&A - mining concession & value chain

2,194

0

2,194

0

Total Pre-Tax Adjustments

7,486

5,045

20,193

11,983

Income tax effects on Adjustments

2,383

857

5,831

3,097

Tax reform and foreign exchange adjustments

660

17,286

(5,322

)

17,286

Adjusted Net Income

$10,583

$10,191

$45,111

$48,617

Adjusted Diluted Earnings Per Participating Share

$0.54

$0.52

$2.28

$2.46

Adjusted EBITDA Reconciliation to Net Income

(Dollars in thousands)

Three Months EndedDecember 31,

Twelve Months EndedDecember 31,

2018

2017

2018

2017

Net Income

$4,820

($11,283

)

$36,071

$22,445

Interest expense, net

3,993

2,572

13,523

7,008

Provision for income taxes

3,006

18,515

7,161

34,192

Depreciation & amortization

11,614

11,395

44,931

40,404

EBITDA

23,433

21,199

101,686

104,049

Adjustments

Non-cash stock compensation

1,044

827

5,187

3,823

Foreign exchange loss (gain)

119

(543

)

528

(578

)

Severance/Restructuring expense

(51

)

358

2,530

2,982

Inventory fair value adjustment

0

2,905

0

4,300

M&A related costs

1,212

2,325

2,194

5,279

Mexico natural gas supply imbalance charges

970

0

2,827

0

Value chain transition

3,002

0

9,880

0

Other

40

0

40

0

Adjusted EBITDA

$29,769

$27,071

$124,872

$119,855

Percent of Sales

15.4

%

14.0

%

15.6

%

16.6

%

Segment Adjusted EBITDA Reconciliation to EBITDA

(Dollars in thousands)

Three Months Ended

Three Months Ended

December 31, 2018

December 31, 2017

FHN

IS

Other

Total

FHN

IS

Other

Total

EBITDA

$13,297

$7,351

$2,783

$23,431

$18,058

$2,167

$973

$21,198

Non-cash stock compensation

591

414

40

1,045

468

327

31

826

Foreign exchange loss (gain)

(38

)

—

157

119

(76

)

—

(467

)

(543

)

Severance/Restructuring exp(inc)

(2

)

(43

)

(7

)

(52

)

209

132

17

358

Inventory fair value adjustment

—

—

—

—

2,905

—

—

2,905

M&A related costs

1,212

—

—

1,212

—

—

2,325

2,325

Mexico natural gas supply adj.

216

455

299

970

—

—

—

—

Value chain transition

1,493

1,442

66

3,001

—

—

—

—

Other

22

15

3

40

—

—

—

—

Adjusted EBITDA

$16,792

$9,634

$3,341

$29,767

$21,564

$2,626

$2,879

$27,069

Twelve Months Ended

Twelve Months Ended

December 31, 2018

December 31, 2017

FHN

IS

Other

Total

FHN

IS

Other

Total

EBITDA

$61,791

$34,124

$5,771

$101,686

$67,156

$33,833

$3,060

$104,049

Non-cash stock compensation

2,936

2,054

197

5,187

2,164

1,514

145

3,823

Foreign exchange loss (gain)

38

—

490

528

(176

)

—

(402

)

(578

)

Severance/Restructuring exp(inc)

1,526

879

125

2,530

1,504

1,435

43

2,982

Inventory fair value adjustment

—

—

—

—

4,300

—

—

4,300

M&A related costs

2,180

—

14

2,194

—

—

5,279

5,279

Mexico natural gas supply adj.

630

1,326

871

2,827

—

—

—

—

Value chain transition

4,068

5,127

685

9,880

—

—

—

—

Other

22

15

3

40

—

—

—

—

Adjusted EBITDA

$73,191

$43,525

$8,156

$124,872

$74,948

$36,782

$8,125

$119,855

Segment Reporting

Three Months EndedDecember 31,

Twelve Months EndedDecember 31,

Segment Net Sales

2018

2017

2018

2017

Food, Health and Nutrition

$113,008

$115,740

$480,166

$397,298

Industrial Specialties

64,838

63,982

260,605

262,704

Other

14,899

13,378

61,071

62,022

Total

$192,745

$193,100

$801,842

$722,024

Net Sales % change

Food, Health and Nutrition

(2.4

)%

20.9

%

Industrial Specialties

1.3

%

(0.8

)%

Other

11.4

%

(1.5

)%

Total

(0.2

)%

11.1

%

Segment EBITDA

Food, Health and Nutrition

$13,297

$18,058

$61,791

$67,156

Industrial Specialties

7,351

2,167

34,124

33,833

Other

2,783

973

5,771

3,060

Total

$23,431

$21,198

$101,686

$104,049

Segment EBITDA % of net sales

Food, Health and Nutrition

11.8

%

15.6

%

12.9

%

16.9

%

Industrial Specialties

11.3

%

3.4

%

13.1

%

12.9

%

Other

18.7

%

7.3

%

9.4

%

4.9

%

Total

12.2

%

11.0

%

12.7

%

14.4

%

Depreciation and amortization expense

Food, Health and Nutrition

$7,018

$7,328

$28,695

$24,212

Industrial Specialties

4,090

3,517

14,347

13,863

Other

506

550

1,889

2,329

Total

$11,614

$11,395

$44,931

$40,404

Price / Volume

The Company calculates pure selling price dollar variances as the
selling price for the current year to date period minus the selling
price for the prior year to date period, and then multiplies the
resulting selling price difference by the prior year to date period
volume. The current quarter selling price dollar variance is derived
from the current quarter year to date selling price dollar variance less
the previous quarter year to date selling price dollar variance. The
selling price dollar variance is then divided by the prior period sales
dollars to calculate the percentage change. Volume/mix variance is
calculated as the total sales variance minus the selling price variance.
The following table illustrates the percentage changes in net sales by
reportable segments compared with the same period of the prior year,
including the effect of selling price and volume/mix changes upon
revenue:

All other including non-cash stock compensation and changes in other
long-term assets and liabilities

11,591

(7,360

)

16,668

(5,443

)

Net cash provided from operation

$

42,745

$

27,332

$

73,612

$

73,989

Cash From Operations Reconciliation to Adjusted
EBITDA

(Dollars in thousands)

Three Months EndedDecember 31,

Twelve Months EndedDecember 31,

2018

2017

2018

2017

Adjusted EBITDA

$

29,769

$

27,071

$

124,872

$

119,855

Operating Working Capital

8,167

11,776

(30,015

)

(14,957

)

Taxes paid

(1,766

)

(866

)

(18,356

)

(14,890

)

Interest paid

(3,972

)

(2,462

)

(14,370

)

(6,753

)

All other including non-cash stock compensation and changes in other
long-term assets and liabilities

10,547

(8,187

)

11,481

(9,266

)

Net cash provided from operation

$

42,745

$

27,332

$

73,612

$

73,989

Free Cash Flow Reconciliation to Cash From
Operations

(Dollars in thousands)

Three Months EndedDecember 31,

Twelve Months EndedDecember 31,

2018

2017

2018

2017

Cash from Operations

$

42,745

$

27,332

$

73,612

$

73,989

Capital Expenditures

(13,442

)

(10,209

)

(56,745

)

(34,859

)

Proceeds from sale leaseback

22,775

0

22,775

0

Free Cash Flow

$

52,078

$

17,123

$

39,642

$

39,130

Summary Balance Sheets

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

(Dollars in thousands)

December 31,2018

December 31,2017

ASSETS

Current assets:

Cash and cash equivalents

$

20,197

$

28,782

Accounts receivable, net

102,564

100,820

Inventories

180,203

145,685

Other current assets

23,654

24,969

Total current assets

326,618

300,256

Property, plant and equipment, net

240,235

219,297

Goodwill

152,767

152,700

Intangibles and other assets, net

95,094

112,916

Total assets

$

814,714

$

785,169

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Current portion of capital leases

$

0

$

4

Accounts payable, trade and other

80,007

70,445

Other current liabilities

49,993

43,084

Total current liabilities

130,000

113,533

Long-term debt

300,000

310,005

Other long-term liabilities

49,199

28,072

Total stockholders' equity

335,515

333,559

Total liabilities and stockholders' equity

$

814,714

$

785,169

Additional Information

Net debt is a supplemental financial measure that is not required by, or
presented in accordance with, US GAAP. The Company believes net debt is
helpful in analyzing leverage and as a performance measure for purposes
of presentation in this release. The Company defines net debt as total
long-term debt (including any current portion) less cash and cash
equivalents.

Free cash flow is a supplemental financial measure that is not required
by, or presented in accordance with, US GAAP. The Company believes free
cash flow is helpful in analyzing the cash flow generating capability of
the business and as a performance measure for purposes of presentation
in this release. The Company defines free cash flow as net cash provided
from operating activities plus cash used for capital expenditures plus
cash received from sale leaseback transactions.

EBITDA, adjusted EBITDA, adjusted net income and adjusted diluted EPS
are supplemental financial measures that are not required by, or
presented in accordance with, US GAAP. The Company believes EBITDA and
adjusted EBITDA are helpful in analyzing the cash flow generating
capability of the business and as performance measures for purposes of
presentation in this release.

Net Working Capital is a supplemental financial measure that is not
required by, or presented in accordance with, US GAAP. The Company
believes net working capital is helpful in analyzing the effects on the
cash flow generating capability of the business and as a performance
measure for purposes of presentation in this release. The Company
defines net working capital as total current assets less cash and cash
equivalents less total current liabilities plus current portion of
capital leases.

Operating Working Capital is a supplemental financial measure that is
not required by, or presented in accordance with, US GAAP. The Company
believes operating working capital is helpful in analyzing the effects
on the cash flow generating capability of the business and as a
performance measure for purposes of presentation in this release. The
Company defines operating working capital as net working capital less
taxes less interest.

Innophos is not able to provide a reconciliation of its expectation for
adjusted earnings to 2019 GAAP net income given the dynamic nature of
the strategic value chain repositioning program expenses and potential
Mexico energy charges that may be incurred. In addition, Innophos is not
able to provide a reconciliation of its 2022 expectation for adjusted
EBITDA margin to GAAP net income due to the number of variables in the
projected EBITDA margin for 2022. As a result we are currently unable to
quantify accurately certain amounts that would be required to be
included in GAAP net income for 2019 or 2022 or the individual
adjustments for such reconciliation. In addition, we believe such
reconciliation would imply a degree of precision that would be confusing
or misleading to investors.